These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23697573)

  • 1. Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study.
    Al-Dabbagh M; Lapphra K; Scheifele DW; Halperin SA; Langley JM; Cho P; Kollmann TR; Li Y; De Serres G; Fortuno ES; Bettinger JA
    Clin Vaccine Immunol; 2013 Aug; 20(8):1108-14. PubMed ID: 23697573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does antigen-specific cytokine response correlate with the experience of oculorespiratory syndrome after influenza vaccine?
    Skowronski DM; Lu H; Warrington R; Hegele RG; De Serres G; HayGlass K; Stark D; White R; Macnabb J; Li Y; Manson HE; Brunham RC
    J Infect Dis; 2003 Feb; 187(3):495-9. PubMed ID: 12552434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza vaccine oculorespiratory syndrome incidence is reduced in HIV.
    Cooper C; Thorne A;
    Vaccine; 2011 Oct; 29(45):7876-7. PubMed ID: 21872629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons.
    De Serres G; Skowronski DM; Guay M; Rochette L; Jacobsen K; Fuller T; Duval B
    Arch Intern Med; 2004 Nov; 164(20):2266-72. PubMed ID: 15534165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oculorespiratory syndrome after influenza immunization in children.
    Skowronski DM; Bjornson G; Husain E; Metzger DL; Scheifele DW
    Pediatr Infect Dis J; 2005 Jan; 24(1):63-9. PubMed ID: 15665712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season.
    Skowronski DM; De Serres G; Hebert J; Stark D; Warrington R; Macnabb J; Shadmani R; Rochette L; MacDonald D; Patrick DM; Duval B
    Vaccine; 2002 Jun; 20(21-22):2713-9. PubMed ID: 12034097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low risk of recurrence of oculorespiratory syndrome following influenza revaccination.
    Skowronski DM; Strauss B; Kendall P; Duval B; De Serres G
    CMAJ; 2002 Oct; 167(8):853-8. PubMed ID: 12406942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected.
    Skowronski DM; De Serres G; Scheifele D; Russell ML; Warrington R; Davies HD; Dionne M; Duval B; Kellner J; MacDonald J
    Clin Infect Dis; 2003 Oct; 37(8):1059-66. PubMed ID: 14523770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination.
    Talaat KR; Halsey NA; Cox AB; Coles CL; Durbin AP; Ramakrishnan A; Bream JH
    Influenza Other Respir Viruses; 2018 Mar; 12(2):202-210. PubMed ID: 28991404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokine profile and level of antibodies after administration of split-vaccine against influenza to adults].
    Bogomolov SV; Zhirova SN; Kostinov MP
    Zh Mikrobiol Epidemiol Immunobiol; 2008; (5):57-61. PubMed ID: 19006832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Functional Food Mixture "Protector" Reinforces the Protective Immune Parameters against Viral Flu Infection in Mice.
    Mansoor KA; Qadan F; Schmidt M; Qinna NA; Badr M; Matalka KZ
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29890620
    [No Abstract]   [Full Text] [Related]  

  • 14. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW; Ward BJ; Dionne M; Vanderkooi OG; Loeb M; Coleman BL; Li Y;
    Vaccine; 2012 Jul; 30(32):4728-32. PubMed ID: 22652402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.
    Strijbos E; Tannemaat MR; Alleman I; de Meel RHP; Bakker JA; van Beek R; Kroon FP; Rimmelzwaan GF; Verschuuren JJGM
    Vaccine; 2019 Feb; 37(7):919-925. PubMed ID: 30660402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage.
    Merani S; Kuchel GA; Kleppinger A; McElhaney JE
    Exp Gerontol; 2018 Jul; 107():116-125. PubMed ID: 28958701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population.
    Huijskens E; Rossen J; Mulder P; van Beek R; van Vugt H; Verbakel J; Rimmelzwaan G; Koopmans M; Peeters M
    Clin Vaccine Immunol; 2011 Sep; 18(9):1401-5. PubMed ID: 21795459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons.
    De Serres G; Toth E; Ménard S; Grenier JL; Roussel R; Tremblay M; Landry M; Robert Y; Rochette L; Skowronski DM
    Vaccine; 2005 May; 23(28):3726-32. PubMed ID: 15882534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I.
    de Boer T; van Dissel JT; Kuijpers TW; Rimmelzwaan GF; Kroon FP; Ottenhoff TH
    Clin Vaccine Immunol; 2008 Aug; 15(8):1171-5. PubMed ID: 18562567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy.
    Bálint A; Farkas K; Éva PK; Terhes G; Urbán E; Szucs M; Nyári T; Bata Z; Nagy F; Szepes Z; Miheller P; Lorinczy K; Lakatos PL; Lovász B; Tamás S; Kulcsár A; Berényi A; Törocsik D; Daróczi T; Saródi Z; Wittmann T; Molnár T
    Scand J Gastroenterol; 2015 Feb; 50(2):174-81. PubMed ID: 25384624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.